ASCENTAGE PHARMA GROUP (06855) has announced that as of the date of this announcement, the company has granted 696,300 restricted share units under the 2022 Restricted Share Unit Plan to three selected individuals. These awards are equivalent to 696,300 shares. The grants include 393,800 restricted share units awarded to Dr. Yang Dajun, the company's Executive Director and CEO; 283,900 restricted share units awarded to Dr. Zhai Yifan, the company's Chief Medical Officer and a major shareholder; and 18,600 restricted share units awarded to one senior management member.

Additionally, as of the announcement date, the company has granted 513,200 stock options under the Post-IPO Share Option Scheme to Dr. Yang and Dr. Zhai. These options grant the holders the right to subscribe for a total of 513,200 ordinary shares of the company upon exercise. The grant is subject to acceptance by Dr. Yang and Dr. Zhai. Specifically, 298,200 stock options were granted to Dr. Yang, and 215,000 stock options were granted to Dr. Zhai.